Early Study Shows New Cancer-Killing Pill Can Target and Eliminate All Types of Solid Tumors
Scientists have unveiled a groundbreaking cancer-fighting pill that has the potential to revolutionize cancer treatment. The molecule, named AOH1996 after Anna Olivia Healy who tragically lost her life to childhood cancer, has demonstrated an unprecedented capability: the ability to target and eliminate solid cancer tumors while sparing healthy cells.
The drug zeroes in on a protein called proliferating cell nuclear antigen (PCNA), a key player in the growth and multiplication of tumors within the body.
Remarkably, this protein was previously considered ‘undruggable,’ making this achievement all the more significant. Researchers from the City of Hope Hospital in Los Angeles, a renowned cancer center, spearheaded this 20-year endeavor, advancing our understanding of cancer treatment.
The experimental drug exhibited its potential during extensive laboratory tests on various cancer cell types, including breast, prostate, brain, ovarian, cervical, skin, and lung cancers. Impressively, the molecule proved effective against all of these cancerous cells.
The mechanism of action involves disrupting the normal reproductive cycle of cancer cells, impeding the division of damaged DNA-bearing cells, and halting the replication of faulty DNA. This lethal combination forces cancer cells to perish while leaving healthy cells unscathed.
Dr. Linda Malkas, the lead researcher, likened the drug’s selective action to a snowstorm that shuts down an entire airline hub, allowing only cancer cell “flights” to be grounded. Importantly, the molecule demonstrated promise not only as a standalone therapy but also in combination with existing cancer treatments. Initial results have shown tumor growth suppression without inducing toxicity.
Although the breakthrough is incredibly promising, further testing on human subjects is essential. The drug, which has been in development for 20 years, is currently undergoing pre-clinical research at the City of Hope, with Phase 1 clinical trial in humans now underway, marking a critical step toward potential approval and widespread use.
Information for this story was found via Sky News, The Daily Mail, and the sources and companies mentioned. The author has no securities or affiliations related to the organizations discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
